US 12,435,148 B2
Compositions and methods to block and bind CXCR4 to modulate cellular function
Juliane Nguyen, Buffalo, NY (US); and Michael Deci, Amherst, NY (US)
Assigned to The Research Foundation for The State University of New York, Amherst, NY (US)
Appl. No. 17/626,477
Filed by The Research Foundation for The State University of New York, Amherst, NY (US)
PCT Filed Jul. 13, 2020, PCT No. PCT/US2020/041819
§ 371(c)(1), (2) Date Jan. 11, 2022,
PCT Pub. No. WO2021/011480, PCT Pub. Date Jan. 21, 2021.
Claims priority of provisional application 62/873,665, filed on Jul. 12, 2019.
Prior Publication US 2022/0281986 A1, Sep. 8, 2022
Int. Cl. C07K 16/28 (2006.01); A61P 35/00 (2006.01); C07K 14/46 (2006.01)
CPC C07K 16/2866 (2013.01) [A61P 35/00 (2018.01); C07K 14/46 (2013.01); C07K 2317/21 (2013.01); C07K 2317/33 (2013.01); C07K 2317/56 (2013.01); C07K 2317/622 (2013.01); C07K 2317/76 (2013.01); C07K 2317/94 (2013.01)] 6 Claims
 
1. An antibody that is specific for the N-terminal domain of CXCR4 comprising a variable light chain (VL) and a variable heavy chain (VH) wherein:
a) the VL comprises CDRLI denoted by the sequence SGSSSNIGSNYVY (SEQ ID NO: 5), CDRL2, denoted by the sequence RNNQRPS (SEQ ID NO:20), and CDRL3, denoted by the sequence AAWDDSLNGVV (SEQ ID NO:21), and the VH comprises CDRH1, denoted by the sequence NFYIH (SEQ ID NO:6), CDRH2, denoted by the sequence IINPSDGRTTYAQ (SEQ ID NO:22), and CDRH3, denoted by the sequence GGHYSNYFGQPST (SEQ ID NO:23);
b) the VL comprises CDRLI denoted by the sequence SGSSSNIGSNYVY (SEQ ID NO: 5), CDRL2, denoted by the sequence RNNQRPS (SEQ ID NO:20), and CDRL3, denoted by the sequence AAWDDSLSGVI (SEQ ID NO:24), and the VH comprises CDRH1, denoted by the sequence NFYIH (SEQ ID NO:6), CDRH2, denoted by the sequence IINPSDGRTTYAQ (SEQ ID NO:22), and CDRH3, denoted by the sequence GGHYSNYFGQPST (SEQ ID NO:23);
c) the VL comprises CDRLI denoted by the sequence SGSSSNIGSNYVY (SEQ ID NO: 5), CDRL2, denoted by the sequence RNNQRPS (SEQ ID NO:20), and CDRL3, denoted by the sequence ATWDDSLSGVV (SEQ ID NO:25), and the VH comprises CDRH1, denoted by the sequence NFYIH (SEQ ID NO:6), CDRH2, denoted by the sequence IINPSDGRTTYAQ (SEQ ID NO:22), and CDRH3, denoted by the sequence GGHYSNYFGQPST (SEQ ID NO:23); or
d) the VL comprises CDRLI denoted by the sequence SGSGSNIGSHTVS (SEQ ID NO: 26), CDRL2, denoted by the sequence GNNNRPS (SEQ ID NO:27), and CDRL3, denoted by the sequence ATWDTGPSAVV (SEQ ID NO:28), and the VH comprises CDRH1, denoted by the sequence NFYIH (SEQ ID NO:6), CDRH2, denoted by the sequence IINPSDGRTTYAQ (SEQ ID NO:22), and CDRH3, denoted by the sequence GGHYSNYFGQPST (SEQ ID NO:23).